Eribulin Medac
Antineoplastic agent for metastatic breast cancer and liposarcoma
Eribulin medac is a prescription antineoplastic (anticancer) medication containing eribulin mesilate, a synthetic analogue of halichondrin B. It is administered intravenously and is approved for the treatment of locally advanced or metastatic breast cancer in adults who have progressed after at least one prior chemotherapy regimen, as well as for unresectable liposarcoma in adults who have previously received anthracycline-based therapy. Eribulin works by disrupting microtubule dynamics, leading to cell cycle arrest and cancer cell death.
Quick Facts
Key Takeaways
- Eribulin medac is a chemotherapy drug given by intravenous injection on days 1 and 8 of a 21-day cycle for metastatic breast cancer and liposarcoma.
- It works through a unique mechanism of action among microtubule-targeting agents, binding specifically to the growing ends of microtubules.
- Severe neutropenia is the most common serious side effect, requiring regular blood count monitoring before and during treatment.
- Eribulin is contraindicated during pregnancy and breastfeeding; effective contraception is mandatory during treatment and for at least 3 months after the last dose.
- The EMBRACE trial demonstrated a statistically significant improvement in overall survival compared to treatment of physician's choice in heavily pretreated metastatic breast cancer patients.
What Is Eribulin Medac and What Is It Used For?
Eribulin medac belongs to a class of chemotherapy agents known as halichondrin B analogues. It is a fully synthetic derivative of halichondrin B, a natural compound originally isolated from the marine sponge Halichondria okadai. The active substance, eribulin mesilate, works by interfering with the dynamic assembly of microtubules, which are essential structural components involved in cell division. By disrupting this process, eribulin causes cancer cells to become arrested in the mitotic phase of the cell cycle, ultimately leading to programmed cell death (apoptosis).
The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have approved eribulin for two primary indications. In the context of breast cancer, eribulin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapy regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane, either in the adjuvant or metastatic setting, unless patients were not suitable for these treatments. This positioning reflects eribulin's role as a later-line therapy option when other standard treatments have failed.
The second approved indication is for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline-containing therapy for advanced or metastatic disease. Liposarcoma is a relatively rare type of soft tissue sarcoma that arises from fat cells. Treatment options for advanced liposarcoma are limited, making eribulin an important addition to the therapeutic landscape for this condition. The approval in liposarcoma was primarily based on the Phase III Study 309 trial, which demonstrated a significant improvement in overall survival compared with dacarbazine.
Unlike some other microtubule-targeting agents such as taxanes (paclitaxel, docetaxel) that stabilize microtubules, or vinca alkaloids (vincristine, vinblastine) that inhibit tubulin polymerization, eribulin has a distinct mechanism. It binds specifically to the growing plus ends of microtubules, suppressing microtubule growth without affecting the shortening phase. This unique binding profile means that eribulin can sometimes retain clinical activity in tumors that have developed resistance to other tubulin-targeting drugs, providing an important treatment option for patients with few remaining therapeutic alternatives.
Eribulin medac is a generic version of the originator product Halaven. As a biosimilar/generic oncology product, it contains the same active substance (eribulin mesilate) at the same strength (0.44 mg/mL solution for injection) and is administered by the same route. The clinical efficacy and safety profile is expected to be equivalent to the originator product based on comprehensive bioequivalence studies and the established regulatory framework for generic medicines in the European Union.
What Should You Know Before Taking Eribulin Medac?
Before treatment with eribulin medac is initiated, your oncologist will conduct a thorough assessment of your medical history, current health status, and potential risk factors. This evaluation is essential because eribulin is a potent cytotoxic agent with significant effects on rapidly dividing cells, including both cancer cells and certain normal cells such as those in the bone marrow and peripheral nervous system. Understanding the contraindications, warnings, and precautions associated with eribulin is critical for ensuring safe and effective treatment.
Contraindications
Eribulin medac must not be used in patients with a known hypersensitivity to eribulin mesilate or to any of the excipients listed in the product information. It is also contraindicated during pregnancy and breastfeeding due to the risk of embryo-fetal toxicity. Women of childbearing potential must confirm they are not pregnant before starting treatment, and effective contraception must be used throughout treatment and for at least 3 months after the last dose.
Eribulin should not be administered to patients with severe hepatic impairment (Child-Pugh class C), as the drug is primarily metabolized by the liver and impaired hepatic function can lead to dangerously elevated drug levels and increased toxicity. Patients with severe bone marrow suppression (neutrophil count below 1.5 × 109/L or platelet count below 75 × 109/L) should not receive eribulin until blood counts have recovered to acceptable levels.
Warnings and Precautions
Severe neutropenia (low white blood cell count) is the most common serious adverse effect of eribulin. Complete blood counts must be performed before each dose. Treatment should be delayed if the absolute neutrophil count is below 1.0 × 109/L on day 1, or below 0.5 × 109/L on day 8, or if platelets are below 75 × 109/L on day 1 or day 8.
Myelosuppression: Eribulin causes dose-dependent bone marrow suppression, primarily manifesting as neutropenia. In clinical trials, Grade 3 or 4 neutropenia occurred in approximately 45-54% of patients, and febrile neutropenia (neutropenia with fever indicating potential infection) occurred in approximately 4-5% of patients. Patients should be closely monitored for signs and symptoms of infection throughout treatment. Growth factor support (G-CSF) may be considered in accordance with institutional guidelines.
Peripheral neuropathy: Eribulin can cause peripheral neuropathy, typically manifesting as numbness, tingling, or pain in the hands and feet. In clinical trials, peripheral neuropathy of any grade occurred in approximately 35% of patients, with Grade 3 or 4 neuropathy in approximately 8%. Patients with pre-existing neuropathy may be at increased risk. If Grade 3 or 4 neuropathy develops, eribulin should be withheld until improvement to Grade 2 or less, and then resumed at a reduced dose.
QT prolongation: Eribulin has been associated with QT interval prolongation on the electrocardiogram (ECG). Caution is warranted in patients with pre-existing QT prolongation, congestive heart failure, bradyarrhythmias, or electrolyte imbalances (particularly hypokalemia or hypomagnesemia). ECG monitoring should be considered in patients at risk, and electrolyte abnormalities should be corrected before starting treatment.
Hepatic impairment: Patients with mild to moderate hepatic impairment (Child-Pugh class A or B) may require dose reductions. Eribulin exposure is increased in patients with hepatic impairment, which may increase the risk and severity of adverse effects. Liver function should be assessed before starting treatment and monitored periodically during therapy.
Pregnancy and Breastfeeding
Eribulin medac is contraindicated during pregnancy. Animal reproductive toxicity studies have demonstrated embryo-fetal toxicity at doses below those used clinically, including increased embryo-fetal death, decreased fetal weight, and teratogenic effects. There are no adequate data from the use of eribulin in pregnant women. If the patient becomes pregnant during treatment, she must be informed of the potential hazard to the fetus.
Women of childbearing potential must use effective contraception during treatment and for at least 3 months after the final dose. Male patients with female partners of childbearing potential should also use effective contraception during treatment and for 3 months after the last dose, as eribulin may impair male fertility based on nonclinical findings.
It is not known whether eribulin or its metabolites are excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding must be discontinued during treatment with eribulin and for at least 3 months after the last dose. The decision to discontinue breastfeeding or to discontinue therapy should take into account the benefit of therapy for the mother.
How Does Eribulin Medac Interact with Other Drugs?
Drug interactions are an important consideration in oncology, where patients often receive multiple medications concurrently. Eribulin is primarily metabolized by CYP3A4 to a minor extent, and it is also a substrate of P-glycoprotein (P-gp). However, in vitro studies suggest that eribulin does not significantly inhibit or induce CYP enzymes at clinically relevant concentrations, which limits its potential for pharmacokinetic drug interactions with many commonly used medications.
Despite this relatively favorable interaction profile, several important drug interactions and precautions should be noted. The following table summarizes the key known and potential interactions with eribulin.
| Interacting Drug/Class | Type | Effect | Recommendation |
|---|---|---|---|
| QT-prolonging drugs (e.g., amiodarone, sotalol, ondansetron) | Pharmacodynamic | Additive risk of QT prolongation and cardiac arrhythmias | Use with caution; ECG monitoring recommended |
| Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) | Pharmacokinetic | Potential increase in eribulin plasma concentrations | Use with caution; monitor for increased toxicity |
| Strong CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine) | Pharmacokinetic | Potential decrease in eribulin plasma concentrations | Use with caution; may reduce efficacy |
| P-glycoprotein inhibitors (e.g., cyclosporin, verapamil) | Pharmacokinetic | May increase eribulin exposure | Monitor for increased adverse effects |
| Live vaccines (e.g., BCG, yellow fever, varicella) | Immunological | Risk of disseminated vaccine infection due to immunosuppression | Contraindicated during treatment; use inactivated vaccines instead |
| Anticoagulants (e.g., warfarin) | Pharmacodynamic | Potential altered anticoagulant effect; thrombocytopenia may increase bleeding risk | Monitor INR closely; adjust dose as needed |
Major Interactions
The most clinically significant interaction is with QT-prolonging medications. Since eribulin itself can prolong the QT interval, co-administration with other drugs that share this property may create a cumulative risk of serious cardiac arrhythmias, including torsades de pointes. Patients who require concurrent use of such agents should undergo baseline and periodic ECG monitoring, and electrolyte imbalances (particularly potassium and magnesium) must be corrected before treatment initiation.
Live vaccines represent another important interaction. Because eribulin causes immunosuppression through bone marrow suppression, the administration of live attenuated vaccines during treatment carries a risk of disseminated vaccine-related infection, which can be severe or fatal. Patients should complete any necessary live vaccinations at least 4 weeks before starting eribulin therapy. Inactivated vaccines can generally be administered during treatment, although the immune response may be reduced.
Minor Interactions
In vitro studies have shown that eribulin does not significantly inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 at clinically relevant concentrations. It also does not induce CYP1A2, CYP2C9, or CYP3A4. These findings suggest that eribulin is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes. However, as with all cytotoxic agents, patients should inform their healthcare team about all medications, supplements, and herbal products they are taking to allow for comprehensive drug interaction screening.
What Is the Correct Dosage of Eribulin Medac?
Eribulin medac must be prescribed and administered by healthcare professionals experienced in the use of cytotoxic chemotherapy. The dosing is based on body surface area (BSA), which is calculated from the patient's height and weight. Accurate BSA calculation is essential for determining the correct dose and minimizing the risk of under- or over-dosing.
Adults
Standard Adult Dose
The recommended dose is 1.23 mg/m² eribulin (equivalent to 1.4 mg/m² eribulin mesilate), administered intravenously over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle. Treatment is continued until disease progression or unacceptable toxicity.
| Condition | Recommended Dose | Notes |
|---|---|---|
| Normal hepatic function | 1.23 mg/m² | Standard dose on days 1 and 8 of 21-day cycle |
| Mild hepatic impairment (Child-Pugh A) | 0.97 mg/m² | Reduced dose due to increased drug exposure |
| Moderate hepatic impairment (Child-Pugh B) | 0.62 mg/m² | Reduced dose due to significantly increased drug exposure |
| Severe hepatic impairment (Child-Pugh C) | Contraindicated | Do not use |
| Moderate renal impairment (CrCl 30-50 mL/min) | 1.23 mg/m² | Standard dose; monitor closely for toxicity |
| First dose reduction (for toxicity) | 0.97 mg/m² | For Grade 3/4 neutropenia, febrile neutropenia, or Grade 3 neuropathy |
| Second dose reduction (for toxicity) | 0.62 mg/m² | If toxicity recurs after first reduction |
Children and Adolescents
The safety and efficacy of eribulin in children and adolescents (under 18 years of age) have not been established. There is no relevant use of eribulin in the pediatric population for the approved indications of metastatic breast cancer and liposarcoma. Therefore, eribulin should not be used in this age group. Pediatric oncology treatment should follow specific pediatric cancer protocols established by specialist pediatric oncology centers.
Elderly Patients
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients may have reduced hepatic and renal function, which should be assessed before treatment initiation. In clinical trials, patients aged 65 years and older demonstrated a similar safety profile to younger patients, although elderly patients may be more susceptible to certain adverse effects such as fatigue, neuropathy, and myelosuppression. Close monitoring is recommended, particularly during the first cycles of treatment.
Missed Dose
If a scheduled dose of eribulin is missed or delayed (for example, due to adverse effects or logistical reasons), it should be administered as soon as it is reasonably practical. The day 8 dose should be delayed if the absolute neutrophil count is below 1.0 × 109/L, or platelets are below 75 × 109/L, or if the patient has experienced Grade 3 or 4 non-hematological toxicity. The next cycle should not begin until the absolute neutrophil count has recovered to at least 1.5 × 109/L and non-hematological toxicities have resolved to Grade 1 or baseline.
Overdose
There is no specific antidote for eribulin overdose. In the event of overdose, the patient should be closely monitored and receive supportive care, with particular attention to potential myelosuppression, peripheral neuropathy, and cardiac effects including QT prolongation. Overdose may result in severe neutropenia, infections, and other serious complications. Management should include blood count monitoring, empiric antibiotics if infection is suspected, growth factor support, and ECG monitoring. Hospitalization in a specialized oncology unit is recommended for observation and management of anticipated complications.
What Are the Side Effects of Eribulin Medac?
Like all chemotherapy agents, eribulin medac can cause side effects, although not everyone experiences them and their severity varies between individuals. The adverse effects of eribulin reflect its mechanism of action on rapidly dividing cells and its effects on the peripheral nervous system. Clinical trials involving over 1,500 patients have established a well-characterized safety profile. The following classification is based on the frequency convention used by the European Medicines Agency and organized by system organ class.
It is important to report any new or worsening symptoms to your healthcare team promptly. Many side effects can be managed with supportive care, dose adjustments, or treatment delays. Your oncologist will weigh the benefits of continued treatment against the severity of side effects when making treatment decisions.
Very Common (affects more than 1 in 10 patients)
- Neutropenia – low white blood cell count; the most frequent serious adverse effect (up to 54% of patients)
- Leukopenia – decreased overall white blood cell count
- Anaemia – low red blood cell count, causing fatigue and shortness of breath
- Fatigue/asthenia – extreme tiredness and lack of energy
- Nausea – feeling of sickness
- Constipation – difficulty passing stools
- Alopecia – hair loss (typically partial or complete)
- Peripheral neuropathy – numbness, tingling, or pain in hands and feet
- Decreased appetite – reduced desire to eat
- Arthralgia/myalgia – joint and muscle pain
- Weight loss – unintentional decrease in body weight
Common (affects 1 to 10 in 100 patients)
- Febrile neutropenia – neutropenia accompanied by fever, indicating potential serious infection
- Thrombocytopenia – low platelet count, increasing risk of bleeding
- Diarrhoea – loose or frequent stools
- Vomiting – being sick
- Stomatitis – inflammation of the mouth lining
- Abdominal pain – stomach or abdominal discomfort
- Headache – pain in the head
- Dizziness – sensation of lightheadedness or unsteadiness
- Pyrexia – fever
- Dyspnoea – shortness of breath
- Cough – persistent cough
- Insomnia – difficulty sleeping
- Urinary tract infection – infection of the urinary system
- Back pain – pain in the lumbar region
- Rash – skin eruption or irritation
- Increased liver enzymes – elevated ALT, AST values on blood tests
Uncommon (affects 1 to 10 in 1,000 patients)
- Sepsis – serious bloodstream infection, potentially life-threatening
- Pneumonia – lung infection
- Interstitial lung disease – inflammation of lung tissue
- Pancreatitis – inflammation of the pancreas
- Deep vein thrombosis – blood clot in a deep vein
- Pulmonary embolism – blood clot in the lungs
- Hepatotoxicity – liver damage
Rare (affects less than 1 in 1,000 patients)
- QT prolongation – abnormal heart rhythm on ECG, potentially serious
- Torsades de pointes – a specific type of dangerous heart rhythm disturbance
- Stevens-Johnson syndrome – severe skin and mucous membrane reaction
- Toxic epidermal necrolysis – severe skin blistering and peeling
- Severe hypersensitivity reaction – serious allergic reaction to the drug
Contact your healthcare team immediately or go to a hospital emergency department if you experience: fever above 38°C (especially if you have low blood counts), severe difficulty breathing, signs of serious infection (chills, severe pain, confusion), signs of bleeding that won't stop, severe numbness or weakness in your limbs, chest pain or irregular heartbeat, or severe skin reaction with blistering.
How Should You Store Eribulin Medac?
Eribulin medac is a hospital-administered medication, so storage is typically handled by the hospital or clinic pharmacy rather than by patients at home. However, understanding proper storage conditions is important for ensuring the quality and efficacy of the medication. The following guidelines apply to the unopened vials and to the prepared solution.
Unopened vials: Eribulin medac solution for injection should be stored at temperatures not exceeding 25°C. The product does not require refrigeration. Vials should be kept in the original outer carton to protect from light. Like all medications, eribulin should be stored out of the reach and sight of children. The shelf life of the product in its original sealed packaging is typically 36 months when stored correctly.
After opening/dilution: From a microbiological point of view, the product should be used immediately after opening. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. The prepared solution should be used within the timeframe specified in the product information, which is generally within 24 hours when stored at controlled room temperature (15-25°C) or under refrigeration (2-8°C).
Disposal: Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic waste. Eribulin is a cytotoxic agent, and standard precautions for the handling and disposal of anticancer drugs should be followed. Healthcare workers should use appropriate personal protective equipment (gloves, gowns, eye protection) when handling the product. Pregnant healthcare workers should not handle eribulin medac.
What Does Eribulin Medac Contain?
Understanding the composition of eribulin medac is important for healthcare providers when assessing compatibility, potential allergies, and preparation requirements. The product is supplied as a clear, colourless aqueous solution in a single-use glass vial.
Active substance: The active ingredient is eribulin mesilate. Each 1 mL vial contains 0.44 mg of eribulin (equivalent to 0.50 mg of eribulin mesilate). Eribulin mesilate is the salt form of eribulin, a fully synthetic macrocyclic ketone analogue of halichondrin B. The molecular formula is C40H59NO11·CH4O3S, with a molecular weight of approximately 826.0 g/mol for the mesilate salt.
Excipients (inactive ingredients):
- Ethanol – used as a co-solvent to maintain eribulin in solution
- Hydrochloric acid (dilute) – for pH adjustment
- Sodium hydroxide – for pH adjustment
- Water for injections – the primary vehicle for the solution
The solution has a pH of approximately 6.5. The product does not contain preservatives and is intended for single-use only. Any remaining solution in the vial after use should be discarded in accordance with cytotoxic waste protocols. Eribulin medac should not be mixed with other medicinal products in the same infusion line. The infusion line should be flushed with sodium chloride 9 mg/mL (0.9%) solution for injection before and after administration of eribulin.
Each 1 mL vial of eribulin medac contains a small amount of ethanol (alcohol). At the recommended doses, the amount of ethanol administered is very small and unlikely to have any noticeable effects. However, this should be considered in patients with alcoholism, liver disease, epilepsy, or other conditions where even small amounts of alcohol may be relevant, as well as in pregnant or breastfeeding women.
Frequently Asked Questions About Eribulin Medac
Eribulin medac is used to treat locally advanced or metastatic breast cancer in adults who have progressed after at least one chemotherapy regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane. It is also approved for the treatment of unresectable liposarcoma (a type of soft tissue sarcoma) in adults who have received prior anthracycline-containing therapy. Eribulin is a later-line therapy option used when other standard treatments have been tried.
Eribulin is given as a short intravenous injection (over 2 to 5 minutes) on day 1 and day 8 of each 21-day treatment cycle. It is administered in a hospital or clinic by a trained healthcare professional. Treatment continues for as long as it remains effective and side effects are manageable. The duration of treatment varies between patients depending on how well the cancer responds and how well the treatment is tolerated.
Yes, hair loss (alopecia) is a very common side effect of eribulin, affecting a significant proportion of patients. Hair loss may be partial or complete and typically begins within the first few treatment cycles. Hair loss is reversible and hair usually begins to regrow after treatment is completed, although the texture or colour may be different initially. Scalp cooling during treatment may help reduce the extent of hair loss in some patients, though this is not always effective with eribulin. Discuss options with your oncology team.
Regular blood tests are essential during eribulin treatment. A complete blood count (CBC) must be performed before each dose to check your white blood cell count (particularly neutrophils), red blood cells, and platelets. Liver function tests and kidney function tests are also monitored periodically. If your blood counts are too low, your doctor may delay treatment, reduce the dose, or prescribe supportive medications such as growth factors to help your bone marrow recover. These blood tests help your medical team manage your treatment safely.
Eribulin is positioned as a later-line treatment option for metastatic breast cancer, typically used after anthracyclines and taxanes have failed. The landmark EMBRACE trial showed that eribulin improved overall survival by approximately 2.5 months compared with treatment of physician's choice in heavily pretreated patients. It has a distinct mechanism of action from other microtubule-targeting drugs, which means it can work in some cases where taxanes or vinca alkaloids have stopped being effective. Your oncologist will consider your full treatment history, tumour characteristics, and overall health when recommending eribulin or alternative treatments.
All information is based on international medical guidelines and peer-reviewed research: EMA Summary of Product Characteristics (SmPC) for eribulin, FDA prescribing information, ESMO Clinical Practice Guidelines for breast cancer and soft tissue sarcoma, NCCN Guidelines, the EMBRACE trial (Cortes et al., Lancet 2011), and Study 309 for liposarcoma (Schoffski et al., Lancet 2016). All medical claims are based on evidence level 1A from randomized controlled trials and systematic reviews.
References
- European Medicines Agency (EMA). Halaven (eribulin) – Summary of Product Characteristics. EMA/CHMP. Last updated 2025. Available at: ema.europa.eu
- Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011;377(9769):914-923. doi:10.1016/S0140-6736(11)60070-6
- Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology. 2015;33(6):594-601. doi:10.1200/JCO.2013.52.4892
- Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2016;387(10028):1629-1637. doi:10.1016/S0140-6736(15)01283-0
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. nccn.org
- Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology. 2020;31(12):1623-1649. doi:10.1016/j.annonc.2020.09.010
- U.S. Food and Drug Administration (FDA). HALAVEN (eribulin mesylate) – Prescribing Information. FDA. Revised 2024. Available at: fda.gov
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. who.int
- Twelves C, Cortes J, Vahdat L, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Research and Treatment. 2014;148(3):553-561. doi:10.1007/s10549-014-3144-y
- Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clinical Cancer Research. 2015;21(11):2445-2452. doi:10.1158/1078-0432.CCR-14-3252
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians in oncology and clinical pharmacology. All content follows the GRADE evidence framework and is based on peer-reviewed research and international clinical guidelines.
iMedic Medical Editorial Team – Specialists in oncology, clinical pharmacology, and evidence-based medicine. All writers have clinical experience and academic qualifications in relevant medical fields.
iMedic Medical Review Board – Independent panel of board-certified physicians who verify all content against current international guidelines (EMA, FDA, ESMO, NCCN, WHO).
All medical claims in this article are supported by Level 1A evidence (systematic reviews and randomized controlled trials). References include the EMBRACE trial, EMA SmPC, FDA prescribing information, and ESMO/NCCN clinical practice guidelines. This article has no commercial funding or pharmaceutical sponsorship.